Latest Headlines

  1. HiRO And Hallym University Sacred Heart Hospital Sign Strategic MOU To Advance Drug Development 3/19/2025

    Harvest Integrated Research Organization (HiRO), a boutique global CRO, is pleased to announce the signing of a Memorandum of Understanding (MOU) with Hallym University Sacred Heart Hospital in Seoul, South Korea.

  2. Alliance For Genomic Discovery Completes 250,000 Whole Genomes To Accelerate Drug Discovery 3/19/2025

    Illumina Inc. (NASDAQ: ILMN) and Nashville Biosciences, LLC (NashBio), a leading clinical and genomic data company and wholly owned subsidiary of Vanderbilt University Medical Center (VUMC), today announced that 250,000 whole genomes have been sequenced for the Alliance for Genomic Discovery (AGD) initiative.

  3. Sapio Sciences Makes AI-Native Drug Discovery Seamless With NVIDIA BioNeMo 3/19/2025

    Sapio Sciences, the science-aware lab informatics platform, today announced the integration of the NVIDIA BioNeMo platform into the Sapio Lab Informatics Platform.

  4. Pharmacy Professor Lands Prestigious Grant To Advance Drug Discovery 3/18/2025

    A University of Mississippi pharmacy professor and his team will use $1,157,696 in grant funding to study a group of bacteria that have shown to be a significant resource for potential new medications.

  5. CUHK Develops Novel Drug Formulation Method That Increases Efficacy Of Drugs 3/18/2025

    Professor Xu Lei of the Department of Physics at The Chinese University of Hong Kong (CUHK), in collaboration with Harvard University, has developed a unique drug formulation method to address the long-standing issue of low solubility in many drugs.

  6. Helix Launches 23,000-Patient Clinico-Genomic Cohort For Autoimmune Diseases To Advance Drug Discovery And Development 3/18/2025

    Helix, a leader in population genomics and precision health, is announcing a new comprehensive clinico-genomic virtual registry of autoimmune disease patients. Consisting of over 23,000 individuals with conditions such as Lupus, Rheumatoid Arthritis (RA), Psoriasis, Multiple Sclerosis (MS), Hashimoto's disease, Crohn's and many more, it's one of the largest autoimmune cohorts in the world.

  7. Valo Health And nference Announce Long-Term Partnership To Accelerate Human-Centric Drug Discovery And Development 3/18/2025

    Valo Health, Inc. (“Valo”), a biotechnology company focused on transforming the drug discovery and development process using human-centric data and artificial intelligence (AI), today announced a multi-year collaboration with nference, a company dedicated to transforming healthcare by making biomedical knowledge computable.

  8. Precision BioSciences Announces Clearance Of Investigational New Drug Application By The U.S. FDA For First-In-Class PBGENE-HBV Designed To Eliminate Root Cause Of Chronic Hepatitis B 3/17/2025

    Precision BioSciences, Inc., a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for PBGENE-HBV.

  9. Xeris Announces Approval Of Supplemental New Drug Application (sNDA) Of Gvoke VialDx (Glucagon) For Use As A Diagnostic Aid 3/17/2025

    Xeris Biopharma Holdings, Inc., a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that its supplemental new drug application (sNDA) of Gvoke VialDx has received U.S Food and Drug Administration (FDA) approval for use as a diagnostic aid during radiologic examinations to temporarily inhibit movement of the gastrointestinal tract in adult patients.

  10. Taiho Pharmaceutical To Acquire Next-Generation ADC Drug Discovery Company Araris Biotech 3/17/2025

    Taiho Pharmaceutical Co., Ltd. (hereinafter "Taiho Pharmaceutical") and Araris Biotech AG (hereinafter "Araris"), a Swiss biotechnology company developing next-generation antibody drug conjugates (ADCs), announced today that they have entered into a definitive agreement pursuant to which Taiho Pharmaceutical will fully acquire Araris (hereinafter "the Acquisition").